Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. Today, we note that psychedelics are suddenly a hot topic for larger pharmaceutical companies, dissect Patrick Soon-Shiong’s claims on his lung cancer drug, and more.

Pharma is quickly warming to psychedelics

AbbVie’s $1.2 billion move to buy Gilgamesh’s psychedelic candidate is the first time a traditional drugmaker has snapped up an investigational psychedelic — a milestone that analysts say could trigger a wave of follow-on deals, STAT’s Olivia Goldhill writes.

“There’s a huge amount of interest coming in suddenly from pharma,” said Josh Hardman, founder of the media and consulting firm Psychedelic Alpha. “We’ve seen a huge uptick in the last six m

See Full Page